DE60026285D1 - Verfahren zur abschätzung des individuellen risikos einer irreversiblen nervenschädigung, das schritte zur quantitativen bestimmung der pepsinogen-i (pgi) und vitamin b12 konzentrationen umfasst - Google Patents

Verfahren zur abschätzung des individuellen risikos einer irreversiblen nervenschädigung, das schritte zur quantitativen bestimmung der pepsinogen-i (pgi) und vitamin b12 konzentrationen umfasst

Info

Publication number
DE60026285D1
DE60026285D1 DE60026285T DE60026285T DE60026285D1 DE 60026285 D1 DE60026285 D1 DE 60026285D1 DE 60026285 T DE60026285 T DE 60026285T DE 60026285 T DE60026285 T DE 60026285T DE 60026285 D1 DE60026285 D1 DE 60026285D1
Authority
DE
Germany
Prior art keywords
pepsinogen
pgi
vitamin
concentrations
analyte
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60026285T
Other languages
English (en)
Other versions
DE60026285T2 (de
Inventor
Pentti Sipponen
Matti Haerkoenen
Osmo Suovaniemi
Erik Forsblom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biohit Oy
Original Assignee
Biohit Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohit Oy filed Critical Biohit Oy
Application granted granted Critical
Publication of DE60026285D1 publication Critical patent/DE60026285D1/de
Publication of DE60026285T2 publication Critical patent/DE60026285T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96472—Aspartic endopeptidases (3.4.23)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Electrotherapy Devices (AREA)
DE60026285T 1999-04-30 2000-04-28 Verfahren zur abschätzung des individuellen risikos einer irreversiblen nervenschädigung, das schritte zur quantitativen bestimmung der pepsinogen-i (pgi) und vitamin b12 konzentrationen umfasst Expired - Lifetime DE60026285T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI990991 1999-04-30
FI990991A FI990991A (fi) 1999-04-30 1999-04-30 Menetelmä irreversiibeleille neurovahingoille riskialttiin yksikön identifioimiseksi
PCT/FI2000/000376 WO2000067029A1 (en) 1999-04-30 2000-04-28 Method for identifying an individual at risk for irreversible neurodamages, comprising the steps of determining quantitatively the concentration of pepsinogen i (pgi) and vitamin b12

Publications (2)

Publication Number Publication Date
DE60026285D1 true DE60026285D1 (de) 2006-04-27
DE60026285T2 DE60026285T2 (de) 2006-11-09

Family

ID=8554566

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60026285T Expired - Lifetime DE60026285T2 (de) 1999-04-30 2000-04-28 Verfahren zur abschätzung des individuellen risikos einer irreversiblen nervenschädigung, das schritte zur quantitativen bestimmung der pepsinogen-i (pgi) und vitamin b12 konzentrationen umfasst

Country Status (12)

Country Link
EP (1) EP1173764B1 (de)
JP (1) JP2002543430A (de)
CN (1) CN1353816A (de)
AT (1) ATE319088T1 (de)
AU (1) AU4299700A (de)
DE (1) DE60026285T2 (de)
DK (1) DK1173764T3 (de)
ES (1) ES2258453T3 (de)
FI (1) FI990991A (de)
PT (1) PT1173764E (de)
RU (1) RU2224258C2 (de)
WO (1) WO2000067029A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20010019A (fi) * 2001-01-05 2002-07-06 Biohit Oyj Menetelmä atrofisen diagnostisoimiseksi
FI20065542A0 (fi) * 2006-09-01 2006-09-01 Biohit Oyj Menetelmä ja näytteenottopakkaus vatsan limakalvon tilan arvioimiseksi

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI97304C (fi) * 1994-11-16 1996-11-25 Locus Genex Oy Menetelmä mahasyövän riskin seulonnaksi

Also Published As

Publication number Publication date
EP1173764A1 (de) 2002-01-23
ATE319088T1 (de) 2006-03-15
PT1173764E (pt) 2006-06-30
FI990991A (fi) 2000-10-31
FI990991A0 (fi) 1999-04-30
CN1353816A (zh) 2002-06-12
DE60026285T2 (de) 2006-11-09
WO2000067029A1 (en) 2000-11-09
ES2258453T3 (es) 2006-09-01
RU2224258C2 (ru) 2004-02-20
DK1173764T3 (da) 2006-05-08
AU4299700A (en) 2000-11-17
EP1173764B1 (de) 2006-03-01
JP2002543430A (ja) 2002-12-17

Similar Documents

Publication Publication Date Title
WO2003056314A3 (de) Analysensystem zur bestimmung einer analytkonzentration unter berücksichtigung von proben- und analytunabhängigen lichtintensitätsänderungen
ATE378404T1 (de) Verfahren zum nachweis von oxidativem stress sowie kit zur durchführung davon
DE69904956D1 (de) Testsatz und verfahren zur qualitätsprüfung von einem iontophoretischen probenahmesystem
DE69837015D1 (de) Verfahren zur Stabilisierung und Messung von Troponinkomplexen
WO2001075450A3 (en) Fluorescent lifetime assays for non-invasive quantification of analytes
ATE232559T1 (de) Verfahren zur signalverstärkung
WO2003043487A3 (en) Method of using a non-antibody protein to detect and measure an analyte
ATE278805T1 (de) Verfahren zur quantifizierung von cholesterol in lipoproteinen und quantifizierungsreagenzien
DE60239968D1 (de) Sche
WO2004011607A3 (en) Reagent and method for determination of a substance using an immunoaggregator
DE60021369D1 (de) Verfahren zur abschätzung eines magengeschwür-risikos
EP1221620A3 (de) Verfahren zum Ausführen einer Bestimmung der "activated clotting time" mit geringer Empfindlichkeit gegenüber die Anwesenheit des Aprotinins sowie zur Ermittlung der Aprotinin-Empfindlichkeit
DE60315715D1 (de) Verwendung von nicotinamide n-methyltransferase zur diagnose von kolorektalem krebs
ATE333091T1 (de) Verfahren zur messung von blutersatzstoffen
ATE467831T1 (de) Verfahren und vorrichtung zum nachweis flüchtiger analyten in luftproben
DE60310012D1 (de) Verfahren, Assay und Kit zur Quantifizierung von HIV-Proteasehemmer
ATE333510T1 (de) Enzymatische messung von mycophenolsäure
CA2586654A1 (en) Use of asc as a marker for colorectal cancer
ATE437372T1 (de) Verfahren zur messung von proinsulin und c-peptid sowie kit dafür
DE60026285D1 (de) Verfahren zur abschätzung des individuellen risikos einer irreversiblen nervenschädigung, das schritte zur quantitativen bestimmung der pepsinogen-i (pgi) und vitamin b12 konzentrationen umfasst
NO903748D0 (no) Fremgangsmaate ved enzymatisk bestemmelse av analyttkonsentrasjoner.
PT1190245E (pt) Deteccao de alergenos
RU2001132334A (ru) Способ идентификации индивидуума, у которого существует риск необратимых неврологических повреждений, включающий в себя этапы количественного определения концентрации пепсиногена i (pgi) и витамина в12
ATE274702T1 (de) Verwendung derivatisierter reagenzien in chemilumineszenz- und elektrochemilumineszenz- nachweisverfahren
RU2002107982A (ru) Способ идентификации индивидуума с риском сосудистого и ракового заболевания

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: BIOHIT OYJ, HELSINKI, FI

8364 No opposition during term of opposition